Ponatinib
Back to searchMolecule Structure
Scientific Name
Ponatinib
Description of the Drug
Ponatinib is a kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08901
http://www.drugbank.ca/drugs/DB08901
Brand Name(s)
Iclusig
Company Owner(s)
Takeda Pharmaceuticals Usa Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Bcr/Abl fusion protein | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2096618 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL589260 | ||
PharmGKB | PA165980594 | ||
Human Metabolome Database | HMDB0240214 | ||
DrugBank | DB08901 | ||
PubChem: Thomson Pharma | 49848164 | ||
PubChem | 24826799 | ||
LINCS | LSM-1151 | ||
Nikkaji | J2.843.862A | ||
PDBe | 0LI | ||
BindingDB | 50322535 | ||
EPA CompTox Dashboard | DTXSID50241426 | ||
DrugCentral | 4716 | ||
Brenda | 227977 | 213585 | |
ChemicalBook | CB12518324 | ||
Guide to Pharmacology | 5890 | ||
rxnorm | PONATINIB | ICLUSIG | PONATINIB HYDROCHLORIDE |
PubChem: Drugs of the Future | 136350016 | ||
ChEBI | 78543 | ||
ZINC | ZINC000036701290 |